Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
Philipp Harter, Jalid Sehouli, Ignace Vergote, Gwénaël Ferron, Alexander Reuß, Werner Meier, Stefano Greggi, Berit J. Mosgard, Frédèric Selle, Frédéric Guyon, Christophe Pomel, Fabrice Lécuru, Rongyu Zang, Elisabeth Åvall‐Lundqvist, Jae‐Weon Kim, Jordi Ponce, Francesco Raspagliesi, Gunnar B. Kristensen, Jean‐Marc Classe, Peter Hillemanns, Pernille Tine Jensen, Annette Hasenburg, Sadaf Ghaem‐Maghami, Mansoor Raza Mirza, Bente Lund, Alexander Reinthaller, Ana Santaballa, Adeola Olaitan, Felix Hilpert, Andreas du Bois
Abstract
(Abstracted from N Engl J Med 2021;385:2123–2131) Standard of care treatment for advanced ovarian cancer involves primary macroscopic resection of all tumor followed by platinum-based combination chemotherapy with or without additional systemic therapy including bevacizumab or a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor. The Descriptive Evaluation of Preoperative Selection Criteria for Operability in Recurrent Ovarian Cancer (DESKTOP) series aims to assess the role of surgery in management of recurrent ovarian cancer.